Codelac neo syrup 1.5mg / ml 100ml fl

$6.24

Codelac neo syrup 1.5mg / ml 100ml fl

Quantity:

SKU: 1447040272 Categories: , , Tags: ,

Description

Composition
Active substance:
5 ml syrup contains: butamirata citrate – 7.5 mg ;.
Excipients:
Sorbitol (Neosorb 70/70 B, sorbitol syrup) 2025.0 mg, glycerol (glycerin) 1450.0 mg, 95% ethanol (ethyl alcohol 95%) 12.69 mg Sodium saccharinate 3.0 mg, benzoic acid 5 75 mg, 3.0 mg vanillin, sodium hydroxide solution 30% 1.55 mg purified water to 5 mL.
Description:
Colorless liquid with an odor of vanilla.
Product form:
Syrup 1.5 mg / ml.
100 and 200 ml bottles in a dark (amber) glass. One vial together with instructions for use and the measuring spoon is placed in a pile of cardboard.
Contraindications
Increased sensitivity to the drug, fructose intolerance, pregnancy (I term), during breastfeeding. Children up to age 3 years.
Dosage
1.5 mg / ml
Indications
Dry cough of any etiology, including whooping cough; cough suppressants in the preoperative and postoperative surgical interventions and bronchoscopy.
Interaction with other drugs
Any drug interactions are not described for butamirata. In the period of treatment is not recommended to drink alcohol, and drugs that suppress the central nervous system (hypnotics, neuroleptics, tranquilizers and other drugs).
Overdose
Symptoms include nausea, vomiting, drowsiness, diarrhea, dizziness, decreased blood pressure, impaired coordination of movements.
Treatment: activated charcoal, saline laxatives, symptomatic therapy (if indicated).
pharmachologic effect
Pharmacological group:
Antitussive central action.
Pharmacodynamics:
Nonopioid antitussive agent has a direct effect on the cough center. It has antitussive, expectorant, moderate bronchodilatory and anti-inflammatory action, spirometry improves (reduces airway resistance) and blood oxygenation.
Pharmacokinetics:
Suction
After ingestion butamirata rapidly and completely absorbed from the gastrointestinal tract. After receiving 150 mg butamirata maximum concentration of the main metabolite (2-phenylbutyric acid) in plasma is achieved after about 1.5 hours and is 6.4 .mu.g / ml.
Distribution and metabolism
Hydrolysis butamirata initially to 2-phenylbutyric acid and dietilaminoetoksietanola starts in blood. These metabolites also possess antitussive activity, and, like butamirata largely (about 95%) bind to plasma proteins, which leads to their long half-life. 2-phenylbutyric acid is partially metabolized by hydroxylation.
Repeated dose drug accumulation was observed.
breeding
The half-life butamirata – 6 hours. Metabolites are excreted primarily by the kidney. Moreover, 2-phenylbutyric acid mostly appears in the associated form of glucuronic acid.
Pregnancy and breast-feeding
No safety data, use during pregnancy, and it passes through the placental barrier. Use of the drug in the first trimester of pregnancy is contraindicated. In II and III trimester of pregnancy, the use of the drug is possible, taking into account the ratio of benefits to the mother and the potential risk to the fetus.
The penetration of the drug into breast milk has not been studied, so the use of the drug during breast feeding is not recommended.
Conditions of supply of pharmacies
Without recipe.
side effects
The central nervous system: dizziness extending when canceling or reducing the drug dose; drowsiness.
From the digestive system: nausea, diarrhea. Allergic reactions: skin rash, itching.
Other: rash.
special instructions
A syrup as sweeteners comprises sodium saccharin and sorbitol, therefore it can be applied to patients with diabetes.
There is a risk when using the drug in patients with a propensity for the development of drug dependency, with liver disease, alcoholism, epilepsy, brain diseases.
It is recommended to refrain from driving and other activities potentially hazardous activities that require high concentration and speed of psychomotor reactions, because the drug can cause dizziness.
Storage conditions
Store at a temperature not higher than 25 C. Keep out of reach of children.
Dosing and Administration
The syrup is taken orally before a meal.
The syrup is indicated for children: ages 3 to 6 years old – 5 ml 3 times a day; from 6 to 12 years – 10 ml 3 times per day; 12 years and older – 15 ml 3 times a day. Adults – 15 ml 4 times per day.
Before the drug should be used dimensional device.
If cough persists for more than 5 days after the start of treatment, you should consult a doctor.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

OTISIFARM

There are no reviews yet.

Add your review